Published in J Biol Chem on April 15, 2003
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis (2008) 1.48
Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem (2015) 1.24
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res (2013) 1.04
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91
Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res (2015) 0.85
Lipoprotein(a): biology and clinical importance. Clin Biochem Rev (2004) 0.83
Lipoprotein(a): Cellular Effects and Molecular Mechanisms. Cholesterol (2012) 0.82
Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res (2014) 0.80
Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo. Sci Rep (2014) 0.79
Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res (2015) 0.79
Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system. PLoS One (2013) 0.78
Evolving targets for lipid-modifying therapy. EMBO Mol Med (2014) 0.78
Development of Antisense Drugs for Dyslipidemia. J Atheroscler Thromb (2016) 0.76
Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis. G3 (Bethesda) (2016) 0.75
Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction. Heart Vessels (2016) 0.75
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care (2006) 2.26
Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation (2002) 2.17
Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care (2011) 2.15
C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int (2005) 2.13
Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.80
Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.78
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Release of glutamate decarboxylase-65 into the circulation by injured pancreatic islet beta-cells. Endocrinology (2007) 1.61
Correlates of dietary intake in youth with diabetes: results from the SEARCH for diabetes in youth study. J Nutr Educ Behav (2011) 1.56
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Type 1 and Type 2 diabetes in Asian and Pacific Islander U.S. youth: the SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.52
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care (2007) 1.44
Solulin increases clot stability in whole blood from humans and dogs with hemophilia. Blood (2012) 1.44
Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis (2003) 1.42
Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD. Diabetologia (2015) 1.41
Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care (2007) 1.38
High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol (2005) 1.29
Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J Clin Endocrinol Metab (2007) 1.28
Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab (2013) 1.26
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.23
Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem (2004) 1.21
Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int (2002) 1.20
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol (2004) 1.20
Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis (2007) 1.18
Association of type 1 diabetes with month of birth among U.S. youth: The SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.17
Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation (2009) 1.16
The factor V activation paradox. J Biol Chem (2004) 1.16
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab (2010) 1.12
Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med (2006) 1.12
Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem (2004) 1.11
Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.10
Further evidence for two functional forms of prothrombinase each specific for either of the two prothrombin activation cleavages. J Biol Chem (2007) 1.09
Reduced heart rate variability among youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care (2012) 1.08
Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process. J Biol Chem (2002) 1.08
Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol (2012) 1.06
Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. Neurobiol Aging (2006) 1.05
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res (2005) 1.04
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res (2013) 1.04
Cardiovascular risk factors are associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care (2013) 1.01
Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2. J Cell Sci (2003) 1.01
Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage. J Transl Med (2011) 1.00
Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res (2011) 1.00
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol (2002) 1.00
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem (2006) 1.00
Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord (2006) 1.00
Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem (2007) 0.98
Incorporation of factor Va into prothrombinase is required for coordinated cleavage of prothrombin by factor Xa. J Biol Chem (2005) 0.98
First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay--Lp(a) SRM 2B. Clin Chem Lab Med (2004) 0.97
Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol (2003) 0.96
Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem (2002) 0.96
The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism (2005) 0.95
Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood (2007) 0.94
Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res (2005) 0.93
Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. J Lipid Res (2003) 0.93
The structural integrity of anion binding exosite I of thrombin is required and sufficient for timely cleavage and activation of factor V and factor VIII. J Biol Chem (2006) 0.93
Reduced heart rate variability is associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care (2013) 0.92
A control switch for prothrombinase: characterization of a hirudin-like pentapeptide from the COOH terminus of factor Va heavy chain that regulates the rate and pathway for prothrombin activation. J Biol Chem (2006) 0.92
Sugar-sweetened and diet beverage consumption is associated with cardiovascular risk factor profile in youth with type 1 diabetes. Acta Diabetol (2011) 0.92
Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation (2002) 0.92
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91
Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PLoS One (2013) 0.90
Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J Lipid Res (2002) 0.90
A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J Biol Chem (2002) 0.90
Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care (2012) 0.89
The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase. Thromb Haemost (2008) 0.89
Parental longevity and diabetes risk in the Diabetes Prevention Program. J Gerontol A Biol Sci Med Sci (2011) 0.89
Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. J Lipid Res (2008) 0.89
Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies. Clin Chim Acta (2011) 0.89
Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms. Diabetes Care (2008) 0.89
The association between adiponectin/leptin ratio and diabetes type: the SEARCH for Diabetes in Youth Study. J Pediatr (2009) 0.88
An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem (2007) 0.88
Apolipoprotein A1 and B. Clin Lab Med (2006) 0.87
The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem (2003) 0.87
Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry (2006) 0.87
A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med (2002) 0.87
Cardiovascular health in adolescents with type 1 diabetes: the SEARCH CVD study. Pediatr Diabetes (2014) 0.87
Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol (2008) 0.86
Lipoprotein(a) metabolism. Curr Opin Lipidol (2014) 0.86
Correlates of medical nutrition therapy and cardiovascular outcomes in youth with type 1 diabetes. J Nutr Educ Behav (2013) 0.85
HLA-associated phenotypes in youth with autoimmune diabetes. Pediatr Diabetes (2012) 0.84
Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chronic Kidney Dis (2007) 0.84
Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly. J Biol Chem (2003) 0.83
Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom (2014) 0.83
Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem (2008) 0.83